This statistical report, co-authored with the UK Health Security Agency (UKSHA), reports childhood vaccination coverage statistics for England in 2023-24. Data relates to the routine vaccinations offered to all children up to the age of 5 years, derived from the Cover of Vaccination Evaluated Rapidly (COVER). Additional information on children aged 2 and 3 vaccinated against seasonal flu are collected from GPs through UKHSA's ImmForm system.

As of July 17, 2022, it was estimated that around every person aged 75 to 79 years of age in England had received at least two doses of a COVID-19 vaccine. Although the source does mention that this is likely to be an overestimation due to population figures taken from 2020. The data shows that at least a quarter of men under 30 years of age have not yet had two vaccine doses, with women more likely to be vaccinated among younger age groups.

Coronavirus (COVID-19) vaccination rates for people aged 18 years and over in England. Estimates by socio-demographic characteristic, region and local authority.

Age-standardised mortality rates for deaths involving coronavirus (COVID-19), non-COVID-19 deaths and all deaths by vaccination status, broken down by age group.

This statistical report, co-authored with Public Health England (PHE), reports childhood vaccination coverage statistics for England in 2018-19. Data relates to the routine vaccinations offered to all children up to the age of five years, derived from the Cover of Vaccination Evaluated Rapidly (COVER). Additional information on children aged 2 and 3 vaccinated against seasonal flu are collected from GPs through PHE's ImmForm system.

Vaccination rates and odds ratios by socio-demographic group among people living in England.

Vaccinations in London Between 8 December 2020 and 15 September 2021 5,838,305 1st doses and 5,232,885 2nd doses have been administered to London residents. Differences in vaccine roll out between London and the Rest of England London Rest of England Priority Group Vaccinations given Percentage vaccinated Vaccinations given Percentage vaccinated Group 1 Older Adult Care Home Residents 21,883 95% 275,964 96% Older Adult Care Home Staff 29,405 85% 381,637 88% Group 2 80+ years 251,021 83% 2,368,284 93% Health Care Worker 174,944 99% 1,139,243 100%* Group 3 75 - 79 years 177,665 90% 1,796,408 99% Group 4 70 - 74 years 252,609 90% 2,454,381 97% Clinically Extremely Vulnerable 278,967 88% 1,850,485 95% Group 5 65 - 69 years 285,768 90% 2,381,250 97% Group 6 At Risk or Carer (Under 65) 983,379 78% 6,093,082 88% Younger Adult Care Home Residents 3,822 92% 30,321 93% Group 7 60 - 64 years 373,327 92% 2,748,412 98% Group 8 55 - 59 years 465,276 91% 3,152,412 97% Group 9 50 - 54 years 510,132 90% 3,141,219 95% Data as at 15 September 2021 for age based groups and as at 12 September 2021 for non-age based groups * The number who have received their first dose exceeds the latest official estimate of the population for this group There is considerable uncertainty in the population denominators used to calculate the percentage vaccinated. Comparing implied vaccination rates for multiple sources of denominators provides some indication of uncertainty in the true values. Confidence is higher where the results from multiple sources agree more closely. Because the denominator sources are not fully independent of one another, users should interpret the range of values across sources as indicating the minimum range of uncertainty in the true value. The following datasets can be used to estimate vaccine uptake by age group for London: ONS 2020 mid-year estimates (MYE). This is the population estimate used for age groups throughout the rest of the analysis. Number of people ages 18 and over on the National Immunisation Management Service (NIMS) ONS Public Health Data Asset (PHDA) dataset. This is a linked dataset combining the 2011 Census, the General Practice Extraction Service (GPES) data for pandemic planning and research and the Hospital Episode Statistics (HES). This data covers a subset of the population. Vaccine roll out in London by Ethnic Group Understanding how vaccine uptake varies across different ethnic groups in London is complicated by two issues: Ethnicity information for recipients is unavailable for a very large number of the vaccinations that have been delivered. As a result, estimates of vaccine uptake by ethnic group are highly sensitive to the assumptions about and treatment of the Unknown group in calculations of rates. For vaccinations given to people aged 50 and over in London nearly 10% do not have ethnicity information available, The accuracy of available population denominators by ethnic group is limited. Because ethnicity information is not captured in official estimates of births, deaths, and migration, the available population denominators typically rely on projecting forward patterns captured in the 2011 Census. Subsequent changes to these patterns, particularly with respect to international migration, leads to increasing uncertainty in the accuracy of denominators sources as we move further away from 2011. Comparing estimated population sizes and implied vaccination rates for multiple sources of denominators provides some indication of uncertainty in the true values. Confidence is higher where the results from multiple sources agree more closely. Because the denominator sources are not fully independent of one another, users should interpret the range of values across sources as indicating the minimum range of uncertainty in the true value. The following population estimates are available by Ethnic group for London:

Estimates of the risk of hospital admission for coronavirus (COVID-19) and death involving COVID-19 by vaccination status, overall and by age group, using anonymised linked data from Census 2021. Experimental Statistics.

Outcome definitions

For this analysis, we define a death as involving COVID-19 if either of the ICD-10 codes U07.1 (COVID-19, virus identified) or U07.2 (COVID-19, virus not identified) is mentioned on the death certificate. Information on cause of death coding is available in the User Guide to Mortality Statistics. We use date of occurrance rather than date of registration to give the date of the death.

We define COVID-109 hospitalisation as an inpatient episode in Hospital Episode Statistics where the primary diagnosis was COVID-19, identified by the ICD-19 codes (COVID-19, virus identified) or U07.2 (COVID-19, virus not identified). Where an individual had experienced more than one COVID-19 hospitalisation, the earliest that occurred within the study period was used. We define the date of COVID-19 hospitalisation as the start of the hospital episode.

ICD-10 code

U07.1 :

COVID-19, virus identified

U07.2:

COVID-19, virus not identified

Vaccination status is defined by the dose and the time since the last dose received

Unvaccinated:

no vaccination to less than 21 days post first dose

First dose 21 days to 3 months:

more than or equal to 21 days post second dose to earliest of less than 91 days post first dose or less than 21 days post second dose

First dose 3+ months:

more than or equal to 91 days post first dose to less than 21 days post second dose

Second dose 21 days to 3 months:

more than or equal to 21 days post second dose to earliest of less than 91 days post second dose or less than 21 days post third dose

Second dose 3-6 months:

more than or equal to 91 days post second dose to earliest of less than 182 days post second dose or less than 21 days post third dose

Second dose 6+ months:

more than or equal to 182 days post second dose to less than 21 days post third dose

Third dose 21 days to 3 months:

more than or equal to 21 days post third dose to less than 91 days post third dose

Third dose 3+ months:

more than or equal to 91 days post third dose

Model adjustments

Three sets of model adjustments were used

Age adjusted:

age (as a natural spline)

Age, socio-demographics adjusted:

age (as a natural spline), plus socio-demographic characteristics (sex, region, ethnicity, religion, IMD decile, NSSEC category, highest qualification, English language proficiency, key worker status)

Fully adjusted:

age (as a natural spline), plus socio-demographic characteristics (sex, region, ethnicity, religion, IMD decile, NSSEC category, highest qualification, English language proficiency, key worker status), plus health-related characteristics (disability, self-reported health, care home residency, number of QCovid comorbidities (grouped), BMI category, frailty flag and hospitalisation within the last 21 days.

Age

Age in years is defined on the Census day 2021 (21 March 2021). Age is included in the model as a natural spline with boundary knots at the 10th and 90th centiles and internal knots at the 25th, 50th and 75th centiles. The positions of the knots are calculated separately for the overall model and for each age group for the stratified model.

In December 2020, a survey carried out in the UK found that 61 percent of respondents who indicated they did not want to receive a vaccination against COVID-19 are unwilling to do so because they are worried about unknown side effects of the vaccine. Furthermore, 15 percent of those skeptical of receiving the vaccine don't believe it will be effective. For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

Flu vaccine uptake (%) in school aged children from Reception to Year 6 (age 4 to 11 year olds) between 1st September to the end of January.RationaleInfluenza (also known as Flu) is a highly infectious viral illness spread by droplet infection. The flu vaccination is offered to people who are at greater risk of developing serious complications if they catch the flu. The seasonal influenza programme for England is set out in the Annual Flu Letter. Both the flu letter and the flu plan have the support of the Chief Medical Officer (CMO), Chief Pharmaceutical Officer (CPhO), and Director of Nursing.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine-preventable communicable diseases. Immunisation is one of the most effective healthcare interventions available, and flu vaccines can prevent illness and hospital admissions among these groups of people. Increasing the uptake of the flu vaccine among these high-risk groups should also contribute to easing winter pressure on primary care services and hospital admissions. Coverage is closely related to levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.The UK Health Security Agency (UKHSA) will continue to provide expert advice and monitoring of public health, including immunisation. NHS England now has responsibility for commissioning the flu programme, and GPs continue to play a key role. NHS England teams will ensure that robust plans are in place locally and that high vaccination uptake levels are reached in the clinical risk groups. For more information, see the Green Book chapter 19 on Influenza.The Annual flu letter sets out the national vaccine uptake ambitions each year. In 2021 to 2022, the national ambition was to achieve at least 70% vaccine uptake in school aged children in Reception to Year 6 (age 4 to 11 years old).Definition of numeratorThe total number of children in the respective eligible age cohort that have received at least one dose of influenza vaccine from 1 September in school, pharmacy, and general practice.Definition of denominatorThe total number of children eligible for influenza vaccination in the LA geography and children educated out of school in the LA geography, defined by child age on 31 AugustCaveatsData for ICBs are estimated from local authority data. In most cases, ICBs are coterminous with local authorities, so the ICB figures are precise. In cases where local authorities cross ICB boundaries, the local authority data are proportionally split between ICBs, based on the population located in each ICB.The affected ICBs are:Bath and North East Somerset, Swindon and WiltshireBedfordshire, Luton and Milton KeynesBuckinghamshire, Oxfordshire and Berkshire WestCambridgeshire and PeterboroughFrimleyHampshire and Isle of WightHertfordshire and West EssexHumber and North YorkshireLancashire and South CumbriaNorfolk and WaveneyNorth East and North CumbriaSuffolk and North East EssexSurrey HeartlandsSussexWest YorkshireRead codes are primarily used for data collection purposes to extract vaccine uptake data for patients who fall into one or more of the designated clinical risk groups. The codes identify individuals at risk and therefore eligible for flu vaccination. However, it is important to note that there may be some individuals with conditions not specified in the recommended risk groups for vaccination, who may be offered influenza vaccine by their GP based on clinical judgement and according to advice contained in the flu letter and Green Book, and thus may fall outside the listed read codes. Therefore, it is important to note that for the reasons mentioned, this data should not be used for GP payment purposes.This collection is regularly submitted for approval from the Data Coordination Board (DCB).

Children for whom the local authority is responsible who completed a course of Meningococcal group B (MenB) vaccine at any time by their first birthday as a percentage of all children whose first birthday falls within the time period.RationaleThe MenB vaccine protects against invasive meningococcal disease caused by capsule group B, which most commonly presents as septicaemia, meningitis, or a combination of both. The vaccine was introduced into the routine childhood immunisation programme in September 2015 for babies at 8 and 16 weeks of age, with a booster dose after the first birthday.Vaccination coverage is the best indicator of the level of protection a population has against vaccine-preventable communicable diseases. Coverage is closely correlated with levels of disease. Monitoring coverage helps identify possible drops in immunity before disease levels rise. The MenB vaccine is given to all children under two years old as part of the childhood vaccination programme.Previous evidence shows that highlighting vaccination programmes encourages improvements in uptake levels. This may also be relevant for NICE guidance PH21: Reducing differences in the uptake of immunisations, which aims to increase immunisation uptake among those under 19 years from groups where uptake is low.Definition of numeratorTotal number of children in LA responsible population whose first birthday falls within the time period who received two doses of MenB at any time before their first birthday.Definition of denominatorTotal number of children in LA responsible population whose first birthday falls within the time period. Coverage figures are supplied for patients registered with GPs based in that LA and for unregistered patients who were resident in that LA. The LA responsible population is therefore different from the estimated resident population figures produced by the Office of National Statistics (ONS) for each LA. For the COVER collection, the LA responsible population is usually derived from the population registers held on CHISs.CaveatsFull GP postcodes are used to aggregate data to ICB. The GP-level coverage data is collected by NHS Digital Strategic Data Collection Service (SDCS) and published by the UK Health Security Agency (UKHSA) COVER team. ICB data is experimental and should be treated with caution as it is not an official statistic.MenB primary data are available as National Statistics for the first time in 2017 to 2018. Information on childhood immunisation coverage at ages one, two, and five is collected through the UK COVER collection by UKHSA. These aggregated data are collected from CHISs, computerised systems storing clinical records that support health promotion and prevention activities for children, including immunisation. In England, COVER data are collected for Upper Tier Local Authorities (LAs) using the COVER data collection form. These are established collections based on total populations, not samples.The number of CHIS systems has decreased from over 100 in 2015 to around 70 by mid-2017. As different phases of the digital strategy are implemented across the country, it is anticipated that there may be further temporary local data quality issues associated with the transition. Temporary data quality issues in some London COVER returns during 2017 to 2018 were observed in the quarterly COVER reports as the new Hubs became responsible for generating coverage data. Changes in vaccine coverage within London should therefore be interpreted with caution for the time being.Caution should be exercised when comparing coverage figures over time due to occasional data quality issues reported by some data suppliers. Apparent trends could reflect changes in the quality of data reported as well as real changes in vaccination coverage. While this issue will be more apparent at the local level, it may also impact national figures. Similarly, some caution should be exercised when comparing coverage between different areas where data quality issues have been reported.

Flu vaccine uptake (%) in children aged 2 to 3 years old, who received the flu vaccination between 1st September to the end of February as recorded in the GP record. The February collection has been adopted for our end of season figures from 2017 to 2018. All previous data is the same definitions but until the end of January rather than February to consider data returning from outside the practice and later in practice vaccinations.RationaleInfluenza (also known as Flu) is a highly infectious viral illness spread by droplet infection. The flu vaccination is offered to people who are at greater risk of developing serious complications if they catch the flu. The seasonal influenza programme for England is set out in the Annual Flu Letter. Both the flu letter and the flu plan have the support of the Chief Medical Officer (CMO), Chief Pharmaceutical Officer (CPhO), and Director of Nursing.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine-preventable communicable diseases. Immunisation is one of the most effective healthcare interventions available, and flu vaccines can prevent illness and hospital admissions among these groups of people. Increasing the uptake of the flu vaccine among these high-risk groups should also contribute to easing winter pressure on primary care services and hospital admissions. Coverage is closely related to levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.The UK Health Security Agency (UKHSA) will continue to provide expert advice and monitoring of public health, including immunisation. NHS England now has responsibility for commissioning the flu programme, and GPs continue to play a key role. NHS England teams will ensure that robust plans are in place locally and that high vaccination uptake levels are reached in the clinical risk groups. For more information, see the Green Book chapter 19 on Influenza.The Annual flu letter sets out the national vaccine uptake ambitions each year. In 2021 to 2022, the national ambition was to achieve at least 70% vaccine uptake in those aged 2 to 3 years old. Prior to this, the national vaccine uptake ambition was 75% in line with WHO targets.Definition of numeratorNumerator is the number of vaccinations administered during the influenza season between 1st September and the end of February.Definition of denominatorDenominator is the GP registered population on the date of extraction including patients who have been offered the vaccine but refused it, as the uptake rate is measured against the overall eligible population. For more detailed information please see the user guide, available to view and download from https://www.gov.uk/government/collections/vaccine-uptake#seasonal-flu-vaccine-uptakeCaveatsThis collection has received approval from the Data Coordination Board (DCB).Data is final and represents a percentage of all GP practices in England responding to the final survey. Where a total for England is quoted (e.g., a sum of the number of patients registered and number vaccinated), this is taken from the GP practice sample and is therefore not an extrapolated figure.For definitions of clinical at-risk groups for those aged 6 months to under 65 years, see the annual flu letter published at Annual Flu Programme.The age under 65 clinical at-risk group data includes pregnant women with other risk factors but excludes otherwise 'healthy' pregnant women and carers.All figures are derived from data as extracted from records on GP systems or as submitted by GP practices, Area Teams, and CCGs.Data source: ImmForm website: registered patient GP practice data, Influenza Immunisation Vaccine Uptake Monitoring Programme, OHID.

In December 2020, a survey carried out in the United Kingdom (UK) found that 87 percent of those aged 75 years of age were willing to take the COVID-19 vaccine and will take the vaccine as soon as it was offered to them. The highest support for taking vaccination was reported in the oldest age groups who are most at risk from the effects of contracting the coronavirus. On the other hand, 18 percent of those aged between 35 and 44 years said they did not want to be vaccinated and will do their best to avoid immunization, even if they were asked to do so by the NHS. For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

These data describe pneumococcal polysaccharide vaccine (PPV) uptake for the survey year, for those aged 65 years and over.RationaleVaccination coverage is the best indicator of the level of protection a population will have against vaccine preventable communicable diseases. Coverage is closely related to levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise. Pneumococcal disease is a significant cause of morbidity and mortality. Certain groups are at risk for severe pneumococcal disease, these include young children, the elderly and people who are in clinical risk groups2. Pneumococcal infections can be non invasive such as bronchitis, otitis media or invasive such as septicaemia, pneumonia, meningitis. Cases of invasive pneumococcal infection usually peak in the winter during December and January. The pneumococcal polysaccharide vaccine (PPV) protects against 23 types of Streptococcus pneumoniae bacterium. It is thought that the PPV is around 50 percent to 70 percent effective at preventing more serious types of invasive pneumococcal infection2.Since 1992 the 23 valent PPV has been recommended for people in the clinical risk groups and since 2003, the PPV vaccination programme has expanded to include immunisation to all those aged 65 years and over in England1This indicator was judged to be a valid and an important measure of public health and was therefore included in the public health outcomes framework. Inclusion of these indicators will encourage the continued prioritisation and evaluation and the effectiveness of the PPV vaccination programme and give an indication of uptake at an upper tier Local Authority level. The vaccination surveys measure the proportion of eligible people that have received PPV at any time and the proportion that received PPV during the previous year, providing an opportunity to assess the delivery of the immunisation programme11 Pneumococcal Polysaccharide Vaccine (PPV) coverage report, England, April 2013 to March 2014 [online]. 2015 [cited 2015 Mar]. Available from URL: https://www.gov.uk/government/publications/pneumococcal-polysaccharide-vaccine-ppv-vaccine-coverage-estimates 2 Pneumococcal infections, NHS Choices [online]. 2013 [cited 2013 Dec]. Available from URL: http://www.nhs.uk/conditions/vaccinations/pages/pneumococcal-vaccination.aspxDefinition of numeratorUKHSA provided UTLA level data. Clinical commissioning group (CCG) data is available from https://www.gov.uk/government/collections/vaccine-uptake#ppv-vaccine-uptakeDefinition of denominatorNumber of adults aged 65 years and over. Data from 2013 to 2014 are now available at source at a local authority level. Data prior to 2013 to 2014 were collected at a PCT level and converted to LA level for inclusion in PHOF using the criteria as defined below:Denominators for local authorities are estimated from denominators for PCTs. Denominators for PCTs include all people registered with practices accountable to the PCT, and no data are available to provide resident-based figures. Denominators for local authorities are estimated as follows: (For local authorities that have exactly the same boundary as a PCT, the PCT figure is used as it is the only estimate available for the residents of the PCT and local authority. For local authorities whose boundary is contained wholly within a single PCT, but is not equal to the whole PCT, the LA denominator is estimated as a proportion of the PCT figure, with the exceptions of Isles of Scilly, City of London, Rutland, Cornwall, Hackney and Leicestershire (see below). For local authorities whose boundaries include all or part of more than one PCT, the local authority denominator is estimated by aggregating the appropriate proportions of the denominators for the PCTs whose boundaries include part of the local authority. The appropriate proportions in cases ii and iii are defined according to the resident population (in the appropriate age group) in the calendar year overlapping most of the period of the indicator value (or the most recent available): resident population by Lower Layer Super Output Area were extracted and used to calculate the population resident in every LA PCT overlapping block.To calculate the denominator, each LA PCT overlap is calculated as a proportion of the PCT resident population, and then multiplied by the denominator for the PCT. A LA may overlap several PCTs: the appropriate portions of all the PCTs’ denominators are aggregated to give the denominator estimate for the LA. Expressed as an equation the denominator is calculated as follows: DenominatorLA = ∑ (DenominatorPCT × n/N) summed over all PCTs overlapping the LA where: DenominatorLA = Estimated denominator in the LA n = Population resident in the LA-PCT overlapping block N = Population resident in the PCT DenominatorPCT = Denominator in the PCT For Isles of Scilly, City of London and Rutland, no indicator data are presented (prior to 2013 to 2014), as the local authority makes up a very small proportion of the PCT, and estimates for the LAs based on the PCT figures are unlikely to be representative as they are swamped by the much larger local authority within the same PCT. The estimates for Cornwall, Hackney and Leicestershire local authorities are combined data for Cornwall and Isles of Scilly, City of London and Hackney, and Leicestershire and Rutland respectively in order to ensure that all valid PCT data are included in the England total.Denominators for Cornwall and Isles of Scilly, City of London and Hackney, and Leicestershire and Rutland are not combined for the 2019 to 2020 annual local authority level data."CaveatsThe pneumococcal vaccine uptake collection is a snapshot of GP patients vaccinated currently registered at the time of data extraction. The proportion of GP practices who provided data for the surveys are available from the uptake reports. Data will exclude patients who have received the vaccine but have subsequently died, patients who have since moved, or patients that are vaccinated but have not had their electronic patient record updated by the time of data extraction. Data for local authorities prior to 2013 to 2014 have been estimated from registered PCT level indicators. While the majority of patients registered with practices accountable to a PCT tend to be resident within that PCT, there are, in some PCTs, significant differences between their resident and registered populations. Therefore the estimates for LAs may not always accurately reflect the resident population of the local authority (LA). Please note that the PCT response rate should be checked for data completeness as this will have a knock on effect to the LA values.

This dataset illustrates uptake inequalities of fourth doses of the coronavirus (COVID-19) vaccine using 2021 Census-derived demographic and socio-economic characteristics: age. sex, ethnicity, religion, socio-economic status and self-reported disability and health status.

Vaccination data are produced using linked data from Deaths registrations and Census 2021, National Immunisation Management Service, Hospital Episode Statistics and General Practise Extraction Service data for Pandemic Planning and Research.

Data may differ from weekly administrative vaccination data published by NHS England.

The data source for this dataset is the NI Vaccine Management System (VMS). VMS holds vaccination reports for COVID-19 and influenza vaccines which were either administered in NI or to NI residents. This dataset is an aggregated summary of COVID-19 vaccinations recorded in VMS. It is effectively a day-by-day count of living people vaccinated by dose, age band (on the day that the dataset was extracted from VMS) and LGD of residence. Aggregated summary data from VMS is published daily to the NI COVID-19 Vaccinations Dashboard. This dataset is updated weekly and allows NI vaccination coverage to be included in the GOV.UK Coronavirus (COVID-19) in the UK dashboard.

Title: Dataset for "Non-linear Relationships between COVID-19 and Non-COVID-19 Mortality by Vaccination Status within Age Groups" Author: Ir. A.J. Oostenbrink, Independent Researcher (ORCID: 0009-0003-3495-9519) Description: This dataset supports the study analyzing non-linear relationships between COVID-19 and non-COVID-19 mortality by vaccination status across age groups, using UK Office for National Statistics (ONS) data from January 2021 to May 2023. It includes age-standardized mortality rates for five vaccination statuses (unvaccinated, one dose, two doses, three doses, four or more doses) across six age groups (18–39, 40–49, 50–59, 60–69, 70–79, 80–89, 90+ years). The dataset covers monthly data on COVID-19 mortality, non-COVID-19 mortality, and all-cause mortality, enabling the examination of selection bias and concentration effects. Key variables include relative risks (RRcov, RRnoncov), vaccine effectiveness (VE) curves, and concentration factors, modeled using a power function (RRcov ∝ (RRnoncov)a). Data were sourced from ONS publications (2022, 2023) and processed in Microsoft Excel. The dataset includes appendices with person-years, mortality rates, and VE visualizations, supporting non-linear modeling and bias correction analyses. Raw data are available upon request, adhering to UK data protection regulations.Keywords: COVID-19, vaccine effectiveness, mortality rates, selection bias, non-linear modeling, ONS dataLicense: [CC BY 4.0]Files: Aggregated mortality data (Excel), Appendices I–VI (visualizations and tables)